TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33275107

Group type: EXPERIMENTAL
Intervention: Adaptive goals with immediate reinforcement
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Adaptive goals with delayed reinforcement
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Static goals with immediate reinforcement
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Static goals with delayed reinforcement
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Transportation walking
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Leisure walking
Number of subjects: 512
Study: 33275200

Group type: EXPERIMENTAL
Intervention: First-generation PF-SES
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Second-generation PF-SES
Number of subjects: 643
Study: 33275278

Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Oral calcium
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Oral vitamin B
Number of subjects: 576

Group type: COMPARATOR
Intervention: Oral vitamin D
Number of subjects: 576

Group type: COMPARATOR
Intervention: Oral calcium-vitamin D
Number of subjects: 576
Study: 33275450

Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 0
Study: 33275486

Group type: EXPERIMENTAL
Intervention: Adjuvant ADT
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Neoadjuvant ADT
Number of subjects: 1065
Study: 33276117

Group type: EXPERIMENTAL
Intervention: Type 2 inflammation treatment
Number of subjects: 0
Study: 33276302

Group type: EXPERIMENTAL
Intervention: Medical treatment for ICAD
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: QMRA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PWI
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: VMR
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: EDS
Number of subjects: 105
Study: 33276318

Group type: EXPERIMENTAL
Intervention: WhatsApp video consultation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bedside consultation
Number of subjects: 144
Study: 33276423

Group type: EXPERIMENTAL
Intervention: two-visit primary vaccination schedule (two intradermal 0.1 mL rabies vaccine doses on day 0 and 7)
Number of subjects: 500

Group type: COMPARATOR
Intervention: three-visit primary vaccination schedule (single intradermal 0.1 mL dose on day 0, 7, and 28)
Number of subjects: 500
Study: 33276773

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Light-Touch intervention
Number of subjects: 6
Study: 33277059

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 8687
Study: 33277073

Group type: EXPERIMENTAL
Intervention: Total menaquinones (MKs) intake
Number of subjects: 2286
Study: 33277223

Group type: EXPERIMENTAL
Intervention: LAG-3 expression in HRS cells
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TIM-3 expression in HRS cells
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PD-1 expression in microenvironment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LAG-3 expression in microenvironment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TIM-3 expression in microenvironment
Number of subjects: 57
Study: 33277290

Group type: EXPERIMENTAL
Intervention: Effective survival (primary outcome)
Number of subjects: 4752

Group type: EXPERIMENTAL
Intervention: Overall survival (secondary outcome)
Number of subjects: 4752

Group type: EXPERIMENTAL
Intervention: Indices of disease progression (secondary outcome)
Number of subjects: 4752
Study: 33277400

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33277427

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs), 3 injections spaced 3 months apart.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs).
Number of subjects: 20
Study: 33277620

Group type: EXPERIMENTAL
Intervention: VIDL induction chemotherapy (4 cycles)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Upfront autologous stem cell transplantation (ASCT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: VIDL induction chemotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 27
Study: 33277913

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive therapy (73.7% of recipients)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Ciclosporin-based immunosuppressive therapy (24.3% of recipients)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive therapy
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Ciclosporin-based immunosuppressive therapy
Number of subjects: 1191
Study: 33277991

Group type: EXPERIMENTAL
Intervention: Religiously tailored text messages (two per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-religiously tailored text messages (two per day)
Number of subjects: 50
Study: 33278016

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo re-randomized to ixekizumab
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab (All Exposure Safety Population)
Number of subjects: 363
Study: 33278077

Group type: EXPERIMENTAL
Intervention: Cell-based immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel approaches using innate immune system cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell-based therapies
Number of subjects: 0
Study: 33278125

Group type: EXPERIMENTAL
Intervention: High-dose synthetic ACTH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose synthetic ACTH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 and 30-min serum or salivary cortisol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New hydrocortisone formulations and delivery methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medications in combination with hydrocortisone
Number of subjects: 0
Study: 33278131

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 23
Study: 33278297

Group type: EXPERIMENTAL
Intervention: Current cannabis users
Number of subjects: 3426

Group type: COMPARATOR
Intervention: Current cannabis users pre-legalization
Number of subjects: 3426
Study: 33278365

Group type: EXPERIMENTAL
Intervention: Stand training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nonweight-bearing arm crank ergometry
Number of subjects: 22

Group type: COMPARATOR
Intervention: Locomotor training (previously published data, N=7)
Number of subjects: 22
Study: 33278600

Group type: EXPERIMENTAL
Intervention: High SDmax (> 0.32 m)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Low SDmax (≤ 0.32 m)
Number of subjects: 290
Study: 33278656

Group type: EXPERIMENTAL
Intervention: High fruit and vegetable intake
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dark leafy greens and berries/melons intake
Number of subjects: 600
Study: 33278792

Group type: EXPERIMENTAL
Intervention: imILT protocol treatment using TRANBERG|Thermal Therapy System
Number of subjects: 15
Study: 33279368

Group type: EXPERIMENTAL
Intervention: Outreach education intervention
Number of subjects: 44
Study: 33279876

Group type: EXPERIMENTAL
Intervention: Higher average stress score (measured using the 4-item perceived stress scale)
Number of subjects: 1060
Study: 33279887

Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg oral, weeks 1 and 2), Bortezomib (1.3 mg/m2 subcutaneous, days 1, 4, 8, and 11), Dexamethasone (20 mg oral, day of and the day following bortezomib administration) for 8 cycles (24 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Panobinostat, Bortezomib, Dexamethasone (extension phase)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Panobinostat, Bortezomib, Dexamethasone
Number of subjects: 31
Study: 33280027

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study: 33280227

Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW) over 36 to 48 weeks in 7 steps
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW)
Number of subjects: 88
Study: 33280228

Group type: COMPARATOR
Intervention: Office BP threshold of 140/90 mmHg
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Office BP threshold of 130/80 mmHg
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: AOBP threshold of 130/80 mmHg
Number of subjects: 468
Study: 33280547

Group type: EXPERIMENTAL
Intervention: SAP prediction scores (5 identified scores)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Multivariate models of scores with biomarkers
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Selected biomarkers
Number of subjects: 683
Study: 33280548

Group type: EXPERIMENTAL
Intervention: Presence of any SVD (≥1 SVD marker)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: No SVD
Number of subjects: 1419
Study: 33280550

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Medical management only
Number of subjects: 361
Study: 33281447

Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 33281736

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) at 5-8 L/min, 1 hour per session, 3 times daily
Number of subjects: 37
Study: 33281950

Group type: EXPERIMENTAL
Intervention: Preoperative endocrine therapy (ET) for 3 (±1) weeks
Number of subjects: 407
Study: 33282202

Group type: EXPERIMENTAL
Intervention: LIQ861 (dry-powder inhaled formulation of treprostinil) at doses of 25, 50, 75, 100, 125, and 150 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33282388

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab plus chemotherapy
Number of subjects: 30
Study: 33282726

Group type: EXPERIMENTAL
Intervention: Anlotinib treatment
Number of subjects: 16
Study: 33283229

Group type: EXPERIMENTAL
Intervention: ONSD ultrasound
Number of subjects: 107
Study: 33283264

Group type: COMPARATOR
Intervention: GABA analogues (gabapentin and pregabalin)
Number of subjects: 4466

Group type: COMPARATOR
Intervention: Kappa opioid agonists (nalfurafine)
Number of subjects: 4466

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 4466

Group type: COMPARATOR
Intervention: Oral montelukast, turmeric, zinc sulfate, topical capsaicin
Number of subjects: 4466
Study: 33283580

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 37
Study: 33283989

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 gene editing of CD34+ hematopoietic stem and progenitor cells
Number of subjects: 0
Study: 33283990

Group type: EXPERIMENTAL
Intervention: BCH-BB694 gene therapy (infusion of autologous CD34+ cells transduced with BCH-BB694 lentiviral vector)
Number of subjects: 6
Study: 33284392

Group type: EXPERIMENTAL
Intervention: Single-lumen 5Fr PICCs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triple-lumen 6Fr PICCs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Triple-lumen 7Fr CICC (reference standard)
Number of subjects: 15
Study: 33284423

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80-mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80-mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASAS40 responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASAS40 response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33284467

Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 53
Study: 33284683

Group type: EXPERIMENTAL
Intervention: Clinician practices during the pandemic
Number of subjects: 45

Group type: COMPARATOR
Intervention: Family visits
Number of subjects: 45

Group type: COMPARATOR
Intervention: Virtual visits
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Advocacy roles of clinicians
Number of subjects: 45
Study: 33284717

Group type: EXPERIMENTAL
Intervention: Lightwand intubation using the marked transmitted glow point (1 cm below the vocal cords)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Marking point placement
Number of subjects: 107
Study: 33284780

Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - peer-learning with expert feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - peer-learning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - self-learning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gamified Educational Network (GEN) - control
Number of subjects: 60
Study: 33284946

Group type: EXPERIMENTAL
Intervention: Complete surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical therapy (rituximab, steroids), radiotherapy, or embolization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study: 33285144

Group type: EXPERIMENTAL
Intervention: Thermal ablation of the defect margin after EMR (EMR-T)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional EMR
Number of subjects: 179
Study: 33285563

Group type: EXPERIMENTAL
Intervention: Visual encoding during memory recall using ultra-high-field (7T) fMRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual recall task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encoding-recall similarity analysis
Number of subjects: 0
Study: 33285582

Group type: EXPERIMENTAL
Intervention: Forceps margin biopsy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Polypectomy specimen margins
Number of subjects: 129
Study: 33287189

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, dosage and duration not available
Number of subjects: 0
Study: 33287583

Group type: EXPERIMENTAL
Intervention: Physiologic approaches for follow-up (United States and European Union)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Imaging and blood monitoring (Japan)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Monitoring frequency of autoimmune ILDs (Pulmonologists)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Understanding of progressive fibrosing phenotype
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Assessment methods (Pulmonary function tests, diffusing capacity assessments, pulse oximeter measurements)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Regional differences in treatment approaches
Number of subjects: 574
Study: 33287584

Group type: EXPERIMENTAL
Intervention: Reclassified group (originally severe AS reclassified as moderate AS)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Severe AS group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Mean pressure gradient ≥31 mm Hg in reclassified group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Aortic valve calcium score
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NT-proBNP and myocardial perfusion reserve
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Troponin
Number of subjects: 174
Study: 33287704

Group type: EXPERIMENTAL
Intervention: MwoA patients
Number of subjects: 72
Study: 33287722

Group type: EXPERIMENTAL
Intervention: LdT (600 mg/day) for 24 weeks, followed by LdT monotherapy until 104 weeks
Number of subjects: 108
Study: 33287748

Group type: EXPERIMENTAL
Intervention: Epileptiform discharges or other sharp activity on EEGs
Number of subjects: 86

Group type: COMPARATOR
Intervention: No epileptiform discharges or other sharp activity on EEGs
Number of subjects: 86
Study: 33287907

Group type: EXPERIMENTAL
Intervention: Physical or sexual IPV
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Physical IPV
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Sexual IPV
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Women raised in households with history of IPV
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Women with no formal education
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Husbands with no formal education
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Muslim women
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Women younger than age 30
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Women members of NGO or microcredit organization
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Disclosure of violence
Number of subjects: 3966
Study: 33287910

Group type: EXPERIMENTAL
Intervention: Chest drain removal
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Bladder catheter insertion
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: CVC insertion
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Intra-hospital transport
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Surgical patients
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2130

Group type: EXPERIMENTAL
Intervention: ICU stay duration
Number of subjects: 2130
Study: 33288401

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 156
Study: 33288485

Group type: EXPERIMENTAL
Intervention: Ofatumumab, etoposide, and high-dose cytarabine (OVA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MRD-negative patients
Number of subjects: 27
Study: 33288505

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP measurements
Number of subjects: 37664

Group type: EXPERIMENTAL
Intervention: Major thoracic surgery
Number of subjects: 37664

Group type: EXPERIMENTAL
Intervention: Major nonthoracic surgery
Number of subjects: 37664

Group type: EXPERIMENTAL
Intervention: Low-risk surgery
Number of subjects: 37664

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 37664
Study: 33288587

Group type: EXPERIMENTAL
Intervention: CCR5 inhibition treatment
Number of subjects: 0
Study: 33288660

Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Number of subjects: 105
Study: 33288749

Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in cohort A
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Durvalumab and trametinib given concomitantly in cohort B
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Durvalumab and trametinib given sequentially in cohort C
Number of subjects: 68
Study: 33288819

Group type: EXPERIMENTAL
Intervention: Laparoscopic Partial Nephrectomy after intra-arterial Embolization (LPNE)
Number of subjects: 0
Study: 33289099

Group type: EXPERIMENTAL
Intervention: Paediatric dispersible tablet formulation
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: Paediatric powder for suspension
Number of subjects: 1306
Study: 33289422

Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 481
Study: 33289432

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33289495

Group type: EXPERIMENTAL
Intervention: Implementation of PAM-13 in oncology nursing practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAM-13 implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient's anxiety level, quality of life, and health literacy level
Number of subjects: 0
Study: 33289590

Group type: EXPERIMENTAL
Intervention: Hypomethylating agent (HMA) guadecitabine
Number of subjects: 25

Group type: COMPARATOR
Intervention: HMA-treated patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pre-treatment tumours
Number of subjects: 25
Study: 33289613

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) ventilation MRI using a U-Net-based DCNN model
Number of subjects: 114

Group type: COMPARATOR
Intervention: Noble gas MRI
Number of subjects: 114
Study: 33289660

Group type: EXPERIMENTAL
Intervention: Piezocision combined with buccal alveolar bone regeneration using a tunneling approach
Number of subjects: 10
Study: 33289669

Group type: EXPERIMENTAL
Intervention: My Guide app
Number of subjects: 80

Group type: COMPARATOR
Intervention: My Health app
Number of subjects: 80
Study: 33289680

Group type: EXPERIMENTAL
Intervention: Unfiltered cigarettes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filtered cigarettes
Number of subjects: 40
Study: 33289910

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vitamin E levels
Number of subjects: 234
Study: 33289918

Group type: EXPERIMENTAL
Intervention: Copanlisib with gemcitabine and cisplatin
Number of subjects: 24
Study: 33289920

Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with temozolomide (TMZ)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with irinotecan (IRN)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) at 200 mg every day on D1-7 plus temozolomide (TMZ) at 30 mg/m
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with TMZ or IRN
Number of subjects: 29
Study: 33289956

Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 218
Study: 33289960

Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 140
Study: 33290093

Group type: EXPERIMENTAL
Intervention: Contact force-guided radiofrequency ablation
Number of subjects: 333
Study: 33290245

Group type: EXPERIMENTAL
Intervention: Online Psychotherapy Tool (9-week electronically delivered cognitive behavioral therapy program)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 80
Study: 33290752

Group type: EXPERIMENTAL
Intervention: Somatropin (Norditropin®)
Number of subjects: 328
Study: 33290995

Group type: EXPERIMENTAL
Intervention: Completion of radical hysterectomy (COMPL group, N = 361)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Abandonment of radical hysterectomy (ABAND group, N = 154)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Overall disease-free survival
Number of subjects: 515
Study: 33290994

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 50